Advertisement

 

 

Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study.

Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study.
Author Information (click to view)

Midani D, Parkman HP,


Midani D, Parkman HP, (click to view)

Midani D, Parkman HP,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of neurogastroenterology and motility 22(4) 650-655 doi 10.5056/jnm15203
Abstract
Background/Aims
Serotonin receptor (eg, 5-HT₃) antagonists are used to treat nausea and vomiting from a variety of causes. Granisetron transdermal system (GTS) is an appealing delivery system for patients with gastroparesis. To assess if GTS improves nausea and vomiting and other gastroparesis symptoms in patients with gastroparesis.

Methods
Patients with gastroparesis and symptoms of nausea and vomiting refractory to conventional treatment were treated with GTS. Symptoms of gastroparesis were assessed using a modified Gastroparesis Cardinal Symptom Index (GCSI). Following 2 weeks of treatment, patients were asked to assess their symptoms and indicate their therapeutic response using the Clinical Patient Grading Assessment Scale (CPGAS) reporting if symptoms of nausea and vomiting improved on a scale: 0 = no change to +7 = completely better.

Results
Fifty-one patients received GTS by prescription: average age was 40 ± 17 years, 44 female, 11 diabetics, 23 ± 20% retention at 4 hours on gastric emptying scintigraphy. Thirty-nine of the 51 (76%) patients stated improvement with GTS. There was significant improvement in nausea and vomiting as assessed with CPGAS at 2 weeks (2.28 ± 2.53; P < 0.05). Symptoms of nausea and vomiting significantly improved. Other symptoms including postprandial fullness, loss of appetite, upper abdominal pain, and early satiety improved. Side effects reported included redness at the site of the patch in 7 patients, pruritus in 5, and constipation in 5. Conclusions
GTS was moderately effective in reducing nausea and/or vomiting in 76% of gastroparesis patients. In addition to nausea and vomiting, symptoms of postprandial fullness, loss of appetite, upper abdominal pain, and early satiety also improved.

Submit a Comment

Your email address will not be published. Required fields are marked *

one × five =

[ HIDE/SHOW ]